المؤلفون: Moreno Muñoz, Miguel

المصدر: Arbor; Vol. 184 No. 730 (2008); 277-284 ; Arbor; Vol. 184 Núm. 730 (2008); 277-284 ; 1988-303X ; 0210-1963 ; 10.3989/arbor.2008.i730

مصطلحات موضوعية: Pharmacogenetics, personalized medicine, research ethics, Farmacogenética, medicina individualizada, ética de la investigación

وصف الملف: application/pdf

العلاقة: https://arbor.revistas.csic.es/index.php/arbor/article/view/178/179Test; Bukaveckas, B. L. (2007): “Pharma, clinicians and the lab come together over personalized medicine”, Personalized Medicine, vol. 4(1): 105-108. doi:10.2217/17410541.4.1.105; Burke, W. (2002): “Genetic test evaluation: information needs of clinicians, policy makers, and the public,” Am J Epidemiol., vol. 156(4): 311-8. doi:10.1093/aje/kwf055; Caulfield, T. (1998): “The Commercialization of Human Genetics: A Discussion of Issues Relevant to the Canadian Consumer”, Journal of Consumer Policy, vol. 21(4): 483-526. doi:10.1023/A:1006908823479; Caulfield, T. y Williams-Jones, B. (eds., 1999): The Commercialization of Genetic Research: Ethical, Legal and Policy Issues, Plenum, New York, 1999.; Collins, F. S. (2004): “What we do and don’t know about ‘race’, ‘ethnicity’, genetics and health at the dawn of the genome era”, Nat Genet., 36(11 Suppl): S13-5. doi:10.1038/ng1436; Collins, F. S.; Green, E. D.; Guttmacher, A. E. y Guyer, M. S. (2003): “A vision for the future of genomics research”, Nature, 422(6934): 835-47. doi:10.1038/nature01626; De Palma, A.: Pharmacogenomics and the Brave New World of Personalized Medicine, Cfr. http://www.pharmamanufacturing.com/articles/2006/047.html?page=1Test; Haga, S. B.; Khoury, M. J. y Burke, W. (2003): “Genomic profiling to promote a healthy lifestyle: not ready for prime time”, Nature Genetics, 34, pp. 347-350. doi:10.1038/ng0803-347; Haga, G. (2006): “Prescribing BiDil: Is It Black and White?”, J Am Coll Cardiol, 48: 12-14. doi:10.1016/j.jacc.2006.04.017; Joly, Y. y Knoppers, B. M. (2006): “Pharmacogenomic data sample collection and storage: ethical issues and policy approaches”, Pharmacogenomics, vol. 7 (2): 219-226. doi:10.2217/14622416.7.2.219; Issa, A. M. (2000): “Ethical considerations in clinical pharmacogenomics research”, Trends in Pharmacological Sciences, vol. 21 (7), 247-249. doi:10.1016/S0165-6147(00)01493-0; Knoppers, B.M. y Chadwick, R. (2005): “Human genetic research: Emerging trends in ethics”, Nature, 6: 75-79.; Knoppers, B. M.; Hirtle, M. y Glass, K. C. (1999): “Commercialization of Genetic Research and Public Policy”, Science, vol. 286 (5448): 2277-2278. doi:10.1126/science.286.5448.2277; Lunshof, J. E. (2006): “Personalized medicine: new perspectives-new ethics?”, Personalized Medicine, vol. 3(2): 187-194. doi:10.2217/17410541.3.2.187; Marteau, T. M. y Lerman, C. (2001): BMJ, vol. 322(7S293): 1056-9.; Morgan, T. M.; Krumholz, H. M.; Lifton, R. P. y Spertus, J. A. (2007): “Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study”, JAMA, vol. 297(14): 1551-61. doi:10.1001/jama.297.14.1551; Schlotterbeck, G. et al. (2006): “Metabolic profiling technologies for biomarker discovery in biomedicine and drug development”, Pharmacogenomics, vol. 7(7): 1055-1075. doi:10.2217/14622416.7.7.1055; Siest, G. et al. (2007): “From human genetic variations to prediction of risks and responses to drugs and the environment”, Personalized Medicine, vol. 4 (1): 95-104. doi:10.2217/17410541.4.1.95; Soo-Jin Lee, S. (2006): “The Politics of Hope-Dreaming in a Genomic Age”, Science, 313: 1889. doi:10.1126/science.1132060; Taylor, et al. (2004): “Combination of isosorbide dinitrate and hydralazine in blacks with heart failure”, N Engl J Med., 351: 2049-57. doi:10.1056/NEJMoa042934; Wailoo, K. y Pemberton, S. (2006): The Troubled Dream of Genetic Medicine. Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease, Johns Hopkins University Press, Baltimore.; Wolinsky, H. (2005): “Do-it-yourself diagnosis”, EMBO, reports vol. 6(9): 805-807. doi:10.1038/sj.embor.7400508; Wynne, B. (2005): “Reflexing Complexity. Post-genomic Knowledge and Reductionist Returns in Public Science”, Theory, Culture & Society, vol. 22(5): 67-94. doi:10.1177/0263276405057192; https://arbor.revistas.csic.es/index.php/arbor/article/view/178Test

الإتاحة: https://doi.org/10.3989/arbor.2008.i730.178Test
https://doi.org/10.3989/arbor.2008.i730Test
https://doi.org/10.2217/17410541.4.1.105Test
https://doi.org/10.1093/aje/kwf055Test
https://doi.org/10.1023/A:1006908823479Test
https://doi.org/10.1038/ng1436Test
https://doi.org/10.1038/nature01626Test
https://doi.org/10.1038/ng0803-347Test
https://doi.org/10.2217/14622416.7.2.219Test
https://doi.org/10.1016/S0165-6147Test(00)01493-0

المؤلفون: López de la Vieja, M.ª Teresa

المصدر: Arbor; Vol. 184 No. 730 (2008); 233-245 ; Arbor; Vol. 184 Núm. 730 (2008); 233-245 ; 1988-303X ; 0210-1963 ; 10.3989/arbor.2008.i730

مصطلحات موضوعية: Research Ethics, Bioethics, good practices, governance, accountability, Ética de la investigación, Bioética, buenas prácticas, gobernanza, dar cuenta

وصف الملف: application/pdf

العلاقة: https://arbor.revistas.csic.es/index.php/arbor/article/view/175/176Test; Advisory Committee on Human Radiation Experiments (ACHRE), Final Report, 1994. Carta de Derechos Fundamentales de la Unión Europea, 18.12.2000, C364/8 Código de Nürnberg, 1949.; Commission of the European Communities (2001): European Governance: A White Paper, COM (2001), 428, Brussels. Consejo de Europa (1997): Convenio para la protección de los derechos humanos y la dignidad del ser humano con respecto a las aplicaciones de la Biología y la Medicina, Oviedo. CORDIS FP7.; Council of Europe (2005): Additional Protocol to the Convention on Human Rights and Biomedicine, on Biomedical Research, Strasbourg.; Council of Europe (2006): Recommendation on Research on Biological Materials of Human Origin, Rec(2006)4, March.; Council for International Organizations of medical Sciences (CIOMS) (2002): International Ethical Guidelines for Biomedical Research Involving Human Subjects, Geneva.; European Commission (2003): Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial, Brussels, April 2003, ENTR/FR/BL D.; European Commission (2007): Ethics for Researchers, Brussels.; European Science Foundation (ESF) (2000): “Good Scientific Practice in Research and Scholarship”, European Science Foundation Policy Briefings, December.; Habermas, J. (1998): “Learning by Disasters? A Diagnostic Look Back on the Short 20th Century”, Constellations, 307-320 doi:10.1111/1467-8675.00097; Harkness, J., Lederer, S., Wikler, D. (2001): “Laying Ethical Foundations for Clinical Research”, Bulletin of the World Health Organisation, 79. LEY 14/2007, de 3 de julio, de Investigación biomédica, BOE n.º 159, 4 julio 2007.; London, A. J. (2005): “Justice and the Human Development Approach to International Research”, The Hastings Center Report, January-February, 24-37.; López de la Vieja, M.ª T. (2005): “Dignidad, igualdad. La ‘buena política’ europea”, López de la Vieja, M.ª T. (ed.): Ciudadanos de Europa, Biblioteca Nueva, Madrid, 79-102.; López de la Vieja, M.ª T. (2005): “La Bioética y los ciudadanos”, López de la Vieja, M.ª T. (ed.): Bioética. Entre la Medicina y la Ética, Ediciones Universidad, Salamanca, 41-60.; López de la Vieja, M.ª T. (2005): “Derechos de los animales, deberes de los humanos”, Isegoria, 32, 157-174.; López de la Vieja, M.ª T. (2006): “Posguerra y contracultura. Identidades en la Ética aplicada”, Arbor, 722, 787-795.; Kovach, H.; Neligan, C. y Burall, S. (2003): The Global Accountability Report, The One World Trust, 2002/2003.; Medical Research Council (1997): MRC Guidelines for Good Clinical Practice in Clinical Trials, London.; Medical Research Council (MRC) (2004): Research Involving Human Participants in Developing Societies, London.; Medical Research Council (MRC) (2005): Medical Research Council Position on Research Regulation and Ethics, London.; Medical Research Council (MRC) (2005): Good Research Practice, London.; The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1979), The Belmont Report, April 18.; Nuttfield Council on Bioethics (2002): The Ethics of Research Related to Healthcare in Developing Countries, London.; Nuttfiel Council on Bioethics (2005): The Ethical Research Involving Animals, London.; Parlamento Europeo: Declaración por escrito sobre los experimentos científicos con primates, 23.4.2007, 0040/2007.; Rau, J.: Rede beim Kongress “Differenz annerkennen. Ethik und Behinderung”, Katholischen Akademie Berlin, 5.12.2003.; Real Decreto 1201/2005, de 10 de octubre, sobre protección de los animales utilizados para experimentación y otros fines científicos.; UNESCO (2005): Universal Declaration on Bioethics and Human Rights. United States Department of Health and Human Services (2005): Protection of Human Subjects.; The Weatherall Report (2006): The Use of Non-Humans Primates on Research, London.; Wild, V. y Biller-Andorno, N. (2006): “Mujeres embarazadas como participantes en ensayos clínicos. Dilemas, debates y la discusión ética”, Estudios multidisciplinares de género, 131-141.; World Medical Association (WMA) (1964): Declaration of Helsinki.; https://arbor.revistas.csic.es/index.php/arbor/article/view/175Test

الإتاحة: https://doi.org/10.3989/arbor.2008.i730.175Test
https://doi.org/10.3989/arbor.2008.i730Test
https://arbor.revistas.csic.es/index.php/arbor/article/view/175Test